Cytokinetics says aficamten beats metoprolol in Phase 3 MAPLE-HCM analysis

Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

0.00
  • Cytokinetics flagged new analyses on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy, with results being presented at ESC Heart Failure 2026.
  • In a Phase 3 head-to-head study versus metoprolol, aficamten showed stronger overall improvements across key measures of patient function and disease activity, while metoprolol did not show comparable benefit.
  • Longer-term follow-up from an open-label extension supported durability of effect and a stable safety profile, including no signal of increased rhythm problems over extended treatment.
  • Additional Phase 3 analyses versus placebo indicated aficamten improved heart-structure function linked to exercise capacity, extending evidence beyond symptom relief.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605111006PRIMZONEFULLFEED9717199) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.